Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Phase II retreatment trial with Bexxar commences

June 30, 1998

Schering-Plough acquires Canadian rights to Ribi's melanoma theraccine

June 29, 1998

Orphan drug status granted to Endorex's ImmTher for Ewing's sarcoma

June 29, 1998

CMB-401, an immunoconjugate for the targeted treatment of EOC

June 25, 1998

Positive phase II results for GMK vaccine presented at NCI-EORTC meeting

June 25, 1998

NeoRx begins phase I trial of Pretarget technology in lymphoma

June 25, 1998

Progenics receives payment for cancer vaccine milestone

June 24, 1998

IL-2 fusion protein produces remission in late-stage refractory CTCL

June 23, 1998

Novopharm Biotech's NOVOMAb-G2 IgM completes phase I

June 23, 1998

Russian scientists evaluate the antitumor activity of betaleukin

June 22, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...